Pay vs Performance Disclosure
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Year (1) | Summary Compensation Table Total for CEO | Compensation Actually Paid to CEO(2)(4) | Average Summary Compensation Table Total for Other NEOs | Average Compensation Actually Paid to Other NEOs(3)(4) | Value of Initial Fixed $100 Investment Based on: | IDEXX Net Income (MM) | IDEXX Organic Revenue Growth(7) | ||||||||||||||||||||||
IDEXX TSR(5) | Peer Group TSR(6) | ||||||||||||||||||||||||||||
| 2025 | $14,580,122 | $31,764,374 | $3,058,799 | $5,888,052 | $135.34 | $148.36 | $1,059.5 | 10 | % | ||||||||||||||||||||
| 2024 | $13,007,051 | $2,329,479 | $3,767,208 | $1,520,473 | $82.71 | $129.46 | $887.9 | 6 | % | ||||||||||||||||||||
| 2023 | $11,519,309 | $22,675,198 | $3,313,564 | $6,133,478 | $111.04 | $126.21 | $845.0 | 9 | % | ||||||||||||||||||||
| 2022 | $9,788,388 | ($13,754,140) | $2,782,492 | ($3,411,052) | $81.61 | $123.67 | $679.1 | 7 | % | ||||||||||||||||||||
| 2021 | $9,065,021 | $28,210,038 | $2,848,443 | $8,009,991 | $131.73 | $126.13 | $744.8 | 16 | % | ||||||||||||||||||||
| Year | 2025 ($) | 2024 ($) | 2023 ($) | 2022 ($) | 2021 ($) | ||||||||||||||||||
| Summary Compensation Table for CEO | 14,580,122 | 13,007,051 | 11,519,309 | 9,788,388 | 9,065,021 | ||||||||||||||||||
| Less | Grant date value of Stock Awards granted during fiscal year as reported in the SCT | 5,399,881 | 5,199,755 | 2,187,697 | 1,937,696 | 1,500,029 | |||||||||||||||||
| Less | Grant date value of Option Awards granted during fiscal year as reported in the SCT | 5,400,001 | 5,200,032 | 6,562,842 | 5,812,593 | 4,499,229 | |||||||||||||||||
| Less | Fair value of equity awards at end of the prior year that failed to meet vesting conditions during fiscal year | — | — | — | — | — | |||||||||||||||||
| Plus | Fair value as of year end of outstanding and unvested equity awards granted during fiscal year | 17,786,572 | 6,143,454 | 10,282,274 | 6,449,518 | 8,858,781 | |||||||||||||||||
| Plus (Less) | Change in fair value (comparing year end to the end of prior fiscal year) of equity awards granted in a prior fiscal year that are outstanding and unvested at year end | 9,606,182 | (5,404,510) | 6,759,528 | (15,299,044) | 13,640,628 | |||||||||||||||||
| Plus | Fair value of equity awards on vesting date for equity awards granted and vested during fiscal year | — | — | — | — | — | |||||||||||||||||
| Plus (Less) | Change in fair value (comparing the vesting date to the end of the prior fiscal year) of equity awards granted in a prior fiscal year that vested during the fiscal year | 591,381 | (1,016,729) | 2,864,627 | (6,942,713) | 2,644,866 | |||||||||||||||||
| Compensation Actually Paid to CEO | 31,764,374 | 2,329,479 | 22,675,198 | (13,754,140) | 28,210,038 | ||||||||||||||||||
| Year | 2025 ($) | 2024 ($) | 2023 ($) | 2022 ($) | 2021 ($) | ||||||||||||||||||
| Summary Compensation Table Average for other NEOs | 3,058,799 | 3,767,208 | 3,313,564 | 2,782,492 | 2,848,443 | ||||||||||||||||||
| Less | Grant date value of Stock Awards granted during fiscal year as reported in the SCT | 999,886 | 1,346,745 | 662,577 | 462,560 | 399,899 | |||||||||||||||||
| Less | Grant date value of Option Awards granted during fiscal year as reported in the SCT | 999,957 | 1,346,841 | 1,425,027 | 1,387,558 | 1,199,793 | |||||||||||||||||
| Less | Fair value of equity awards at end of the prior year that failed to meet vesting conditions during fiscal year | 81,164 | — | — | — | — | |||||||||||||||||
| Plus | Fair value as of year end of outstanding and unvested equity awards granted during fiscal year | 3,197,951 | 1,680,575 | 2,418,164 | 1,520,657 | 2,340,819 | |||||||||||||||||
| Plus (Less) | Change in fair value (comparing year end to the end of prior fiscal year) of equity awards granted in a prior fiscal year that are outstanding and unvested at year end | 1,688,947 | (1,191,429) | 1,606,730 | (3,973,866) | 3,751,718 | |||||||||||||||||
| Plus | Fair value of equity awards on vesting date for equity awards granted and vested during fiscal year | — | — | — | — | — | |||||||||||||||||
| Plus (Less) | Change in fair value (comparing the vesting date to the end of the prior fiscal year) of equity awards granted in a prior fiscal year that vested during the fiscal year | 23,363 | (42,295) | 882,624 | (1,890,216) | 668,703 | |||||||||||||||||
| Average Compensation Actually Paid to Other NEOs | 5,888,052 | 1,520,473 | 6,133,478 | (3,411,052) | 8,009,991 | ||||||||||||||||||
Financial Performance Measures(1) | |||||
| Organic revenue growth | Operating profit | ||||
| Earnings per share (diluted) | ROIC | ||||
Pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are required to provide annual disclosure of certain information to describe the relationship between “compensation actually paid” to our CEO and other NEOs and our financial performance. For further information regarding our compensation philosophy and how executive compensation aligns with performance, refer to the discussion under “Compensation Discussion and Analysis” beginning on page 78.
The following pay versus performance table sets forth information required by Item 402(v) of Regulation S-K, including: (i) the total compensation earned by our CEO (as reported on our Summary Compensation Table), (ii) the “compensation actually paid” to our CEO (calculated in accordance with Item 402(v) of Regulation S-K), (iii) the average of the total compensation earned by our other NEOs (derived from our Summary Compensation Table), (iv) the average “compensation actually paid” to our other NEOs (calculated in accordance with Item 402(v) of Regulation S-K), (v) our net income and (vi) our organic revenue growth rate, in each case, for each of the covered fiscal years of 2021, 2022, 2023, 2024 and 2025, as well as our cumulative total shareholder return and that of the S&P 500 Health Care Index (our pay versus performance peer group) over such period.
Equity values used to determine the deductions and additions set forth in the tables in notes (2) and (3) above to calculate “compensation actually paid” for our CEO and average “compensation actually paid” for our other NEOs are calculated in accordance with FASB ASC Topic 718. Adjustments with respect to stock option awards have been made as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility and risk free rates) as of the relevant measurement date in accordance with U.S. GAAP. The methodology used to develop the valuation assumptions as of each relevant measurement date does not differ materially from those disclosed at the time of grant. In the case of PSUs, the valuation assumptions used to calculate the fair market value include the stock price, as well as the probable outcome of the performance vesting conditions, as of the applicable measurement date.
The measurement period to calculate total shareholder return (TSR) begins as of market close on December 31, 2020 and ends on December 31, 2021, 2022, 2023, 2024 and 2025, as applicable. The calculation of TSR assumes an initial investment of $100 as of the close of trading on December 31, 2020, and assumes dividends, if any, were reinvested. As detailed earlier under “Compensation Discussion and Analysis” beginning on page 78, we seek to create alignment between management and shareholder interests. We do so, in part, by compensating our NEOs primarily with variable and “at-risk” compensation elements. In particular, a majority of the value of our NEOs’ target total direct compensation is in the form of long-term equity awards. As a result, the increase in our stock price during 2025 resulted in “compensation actually paid” for our CEO and average “compensation actually paid” for our other NEOs that was significantly higher than the corresponding total compensation amounts reported in the Summary Compensation Table for 2025.
The following graphs describe the relationship between the annual total compensation actually paid to our CEO, the average annual total compensation actually paid to our other NEOs, the total shareholder return of our stock, the total shareholder return of the S&P 500 Health Care Index, our net income and our organic revenue growth rate, as each is disclosed in the pay versus performance table above.
Pursuant to Item 402(v)(6) of Regulation S-K, we are required to provide a tabular list of at least three, and up to seven, financial performance measures which in our assessment represent the most important financial performance measures used by us to link compensation actually paid to our NEOs, for 2025, to our performance.
For a description of the financial performance measures and how they factor into our annual performance-based cash bonus program, refer to the discussion under “Our Financial Performance Factor” beginning on page 95.